Cabotegravir (Apretude®)

Covered: Apretude (cabotegravir IM) is covered only for FDA‑approved PrEP in at‑risk adults and adolescents weighing ≥35 kg and is not covered for persons <35 kg, treatment of established HIV‑1 infection, or post‑exposure prophylaxis. Key requirements: coverage requires documentation of weight ≥35 kg, a negative HIV‑1 test within 1 week, absence of acute HIV symptoms, prescription by or in consultation with an HIV specialist, use as part of a comprehensive prevention strategy with counseling, adherence to the dosing schedule (initiation: two 600 mg IM injections 1 month apart; maintenance: 600 mg IM every 2 months; if oral lead‑in used, injections on last day or within 3 days), and approvals are limited to 12 months.

"Apretude is indicated in at-risk adults and adolescents weighing at least 35 kg for preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection."